A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma (FIRCE-1)
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy
Sponsor: CARGO Therapeutics
Terminated
Company decision to stop trial, withdraw the IND and close down operations.
Listed as NCT05972720, this PHASE2 trial focuses on Cancer and Relapsed/Refractory Large B-cell Lymphoma (LBCL) and remains terminated or withdrawn. Sponsored by CARGO Therapeutics, it has been updated 14 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE2
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Dec 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Aug 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CARGO Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .